Jazz Pharmaceuticals (JAZZ) CEO Gala Renee D Receives Award

What Happened

• Gala Renee D, President & CEO of Jazz Pharmaceuticals (JAZZ), was granted 44,465 restricted stock units (RSUs) on February 26, 2026. The filing reports an acquisition price of $0.00 (typical for RSU grants); the reported total cash value at grant is $0. These RSUs represent contingent rights to receive one ordinary share per unit upon vesting.

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-03-02; appears to be timely within two business days)
• Transaction type/code: Award/Grant (A)
• Units granted: 44,465 restricted stock units (RSUs)
• Reported acquisition price: $0.00 per unit; reported total $0
• Vesting: RSUs granted under the 2011 Equity Incentive Plan; vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026 (1/4 on the first anniversary, then equal annual installments over the next three years)
• Shares owned after transaction: not specified in the provided filing excerpt
• Footnote: Grant is pursuant to the Issuer’s 2011 Equity Incentive Plan (see vesting schedule above)

Context

• RSU grants are compensation awards, not open-market purchases or sales. They vest over time and convert into ordinary shares only upon vesting, so the reported $0 acquisition price reflects the contingent nature of the award rather than market value. This type of filing signals executive compensation alignment rather than an immediate bullish or bearish market action.